Oncology

FDA approves first anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel; ide-cel; Bristol Myers Squibb and bluebird bio, Inc) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after ≥4 prior lines of...